Pilot Study of a Novel 532nm KTP Laser for the Treatment of Fresh Surgical Scars

Scar Clinical Trial

Official title:

Randomized, Controlled, Open-Label Pilot Study of a Novel 532 nm KTP Laser for the Treatment of Fresh Surgical Scars.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01789346
• Other study ID #: C-12-EV03
• Status: Completed
• Phase: N/A
• Start date: February 2013
• Est. completion date: December 2014

Study information

• Verified date: January 2023
• Source: Cutera Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of the 532nm potassium titanyl phosphate (KTP) laser in comparison with the 595nm pulsed-dye laser (PDL) for the treatment of fresh surgical scars.

Description:

Randomized, Controlled, Open-Label Pilot Study of a Novel 532 nm KTP Laser for the Treatment of Fresh Surgical Scars. This is a single-center prospective, randomized, open-label, pilot study of a novel 532 nm KTP Laser in comparison with the 595nm pulsed-dye laser (PDL) in up to 20 subjects who have had a fresh surgical scar acquired within one to twelve months of the screening visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 2014
• Est. primary completion date: March 26, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Fitzpatrick Skin Type I - IV

• Has postoperative linear scar(s) which is one to twelve months post-surgery.

• Having one scar that measures a minimum of 5 cm in length or two scars (bilateral) each measure a minimum of 2 cm in length.

• Be in good health.

• Must agree not to undergo any other procedure for the treatment of scar during the study.

• Willing to refrain from excess sun exposure and willing to wear sunscreen on the treated scar during the study (including the follow-up period).

• Able to read, understand and sign the Informed Consent Form.

• Willing and able to adhere to the treatment and follow-up schedule, and the post-treatment care instructions.

• Willingness to have digital photographs taken of the treated scar.

• Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study.

Exclusion Criteria:

• Participation in a study of another device or drug within 6 months prior to enrollment or during the study.

• Having received any prior treatment for the target surgical scar.

• Pregnant and/or breastfeeding.

• Significant concurrent illness, malignant tumors in the target area, acute or chronic skin infection/inflammation, currently using immunosuppressive medications or currently undergoing systemic chemotherapy.

• Current use of any medication known to increase sensitivity to light or taking prescription anticoagulation medication.

• History of abnormal or delayed wound healing, keloid formation or pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.

• History of malignant skin disease, immune deficiency disorders, coagulation disorders, seizure disorders due to light, or diseases stimulated by heat, unless prophylactic measures taken prior to treatment.

• Systemic use of isotretinoin within 6 months or corticosteroids within 12 months of study participation.

• Anytime in life, had used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus.

• Current smoker or history of smoking within 12 months of study participation.

Related Conditions & MeSH terms

• Cicatrix
• Cicatrix, Hypertrophic
• Hypertrophy
• Keloid
• Scar
• Surgical Scar

Intervention

Device:
• 532nm KTP
up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
• 595nm PDL
up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.

Locations

Country	Name	City	State
United States	Washington Institute of Dermatologic Laser Surgery	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Cutera Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement in Surgical Scar of Treatment (532nm KTP Laser) and Active Control (595nm PDL) Treatment Arms.	Improvement in surgical scar of 532 nm KTP and 595 nm PDL treatment arms at 12 weeks post-final treatment (compared to baseline) as assessed by blinded independent reviewers Physician's Global Assessment (min=0; max=3) Higher scores mean better outcome	12-weeks post-final laser treatment